Compare Novartis AG (NVS) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Shell PLC — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Shell PLC trades at $87.12 (market cap $235.24B). The key difference: Novartis AG is the larger of the two by market cap, and Shell PLC pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVS | SHEL | |
|---|---|---|
Market Cap | $290.25B | $235.24B |
Sector | Health | Energy |
52-Week High | $168.62 | $94.15 |
52-Week Low | $113.50 | $70.31 |
Enterprise Value | $330.27B | $287.77B |
Dividend Yield | 3.17% | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
Shell (SHEL) trades at $87.20, showing modest daily decline but maintaining strong technical momentum with bullish moving averages. The stock offers attractive valuation with P/E of 13.43 and P/S of 0.94, supported by solid profitability metrics including 7.01% net margin and 10.64% ROE. Recent Q1 2026 earnings beat expectations at $2.44 EPS versus $2.14 forecast, while the company expands LNG operations in the Caribbean and advances Venezuela gas projects.
Shell presents compelling value with 30% upside to consensus price target of $114.13, supported by 69% analyst buy ratings. However, investors face risks from volatile oil prices, Middle East production disruptions, and declining cash flow trends. The current technical overbought condition suggests potential near-term consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
